Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
This is the first update to the original CTS communication distributed on July 6th. As previously co...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...